Sinovac Biotech Receives $345 Million Go-Private Offer

Sinovac Biotech, a Beijing vaccine company, has received a privatization offer from management that values the company at $345 million. The offer is priced at $6.18 per share, a 23% premium to Sinovac's previous closing price of $5.02. Sinovac is the last of the US-listed China pharma companies to go private. After two years as private companies, other previously listed pharmas have been conducting new IPOs in Hong Kong, where their companies are given higher multiples and generate big rewards for the privatization investors. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.